KGK Science Inc. has received a growth investment led by Maxim Partners. Financial terms were not disclosed.
KGK, founded in 1997, is a North American contract research organization specializing in clinical trials and regulatory services for the dietary supplement, nutraceutical, and consumer health industries. The company has completed more than 400 clinical trials across over 40 health indications and published more than 150 peer-reviewed publications.
The investment will support expanded clinical trial capacity, decentralized and virtual trial capabilities, and growth of KGK’s regulatory services. Founder and CEO Najla Guthrie and the existing management team will continue to lead the business. MLT Aikins served as legal advisor to Maxim Partners on the transaction.
KEY QUOTES:
“For nearly three decades, KGK has been committed to helping consumer nutrition companies generate the scientific evidence needed to bring innovative products to market. Maxim shares our long-term vision and brings the strategic resources and sector experience to help us expand our capabilities, invest in our team, and better serve our clients around the world.”
Najla Guthrie, Founder and CEO, KGK Science Inc.
“KGK has built a differentiated platform with an outstanding reputation for scientific rigor, regulatory expertise, and customer service. As demand for clinically validated consumer nutrition products continues to grow, we believe KGK is exceptionally well positioned to capitalize on those long-term industry trends.”
Gregg Wilson, Founder and Managing Partner, Maxim Partners
Thank you for visiting Pulse 2.0. We work hard every day to bring leaders and decision makers like you the latest intelligence on business, finance, capital markets, deal flow, law, tech, and AI. Click here to subscribe to the Pulse 2.0 Newsletter.
Stay informed with the day's intelligence on business, finance, capital markets, deal flow, law, tech, and AI delivered to your inbox each evening at 6pm ET.